1. Home
  2. OPHC vs XBIT Comparison

OPHC vs XBIT Comparison

Compare OPHC & XBIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo OptimumBank Holdings Inc.

OPHC

OptimumBank Holdings Inc.

HOLD

Current Price

$7.58

Market Cap

67.5M

Sector

Finance

ML Signal

HOLD

Logo XBiotech Inc.

XBIT

XBiotech Inc.

HOLD

Current Price

$2.24

Market Cap

69.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OPHC
XBIT
Founded
2000
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Pharmaceuticals and Biotechnology
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
67.5M
69.8M
IPO Year
2012
2015

Fundamental Metrics

Financial Performance
Metric
OPHC
XBIT
Price
$7.58
$2.24
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$6.50
N/A
AVG Volume (30 Days)
73.2K
39.8K
Earning Date
04-24-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.20
N/A
Revenue
N/A
N/A
Revenue This Year
$17,095.98
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$35.25
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.91
$2.09
52 Week High
$7.35
$3.61

Technical Indicators

Market Signals
Indicator
OPHC
XBIT
Relative Strength Index (RSI) 82.90 38.13
Support Level $5.33 $2.18
Resistance Level N/A $2.42
Average True Range (ATR) 0.24 0.05
MACD 0.13 -0.00
Stochastic Oscillator 95.54 35.71

Price Performance

Historical Comparison
OPHC
XBIT

About OPHC OptimumBank Holdings Inc.

OptimumBank Holdings Inc serves as a bank holding company for OptimumBank. The Bank provides community banking services to individuals and corporate customers. The services provided by the bank include demand interest-bearing and non-interest-bearing accounts, negotiable order of withdrawal accounts, borrowings, repayment of loans, money market deposit accounts, debit cards, automated teller machines, and other bank related services.

About XBIT XBiotech Inc.

XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.

Share on Social Networks: